Clinical Trial Detail

NCT ID NCT01885195
Title MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Binimetinib

Age Groups: senior adult

Additional content available in CKB BOOST